Keytruda Rules The Roost, But Merck & Co. Highlights Progress In Other Areas
Executive Summary
Merck & Co. outlined its near-term growth drivers during an investor day, including Keytruda in breast and prostate cancer, as well as vaccines for RSV and CMV, a drug for chronic cough and a long-acting HIV medicine.
You may also be interested in...
Merck Buys Peloton On Eve Of IPO, Expands Kidney Cancer Portfolio
Investors in Peloton, which has the only clinical-stage HIF-2α inhibitor, will get back 3.5 times the $304m in venture capital invested in the firm via the $1.1bn that Merck is paying up front. With all $1.15bn in additional milestone fees, the return could grow to 7.2x.
Merck's Keytruda Lead Widens Over Competing Checkpoint Inhibitors
CEO Ken Frazier had to argue the case that Merck has a diversified portfolio in yet another strong quarter for the PD-1 inhibitor Keytruda.
First In 10 Years, But Lenvima's First-Line Liver Label Could Be Challenged Soon
Eisai and Merck won the first US FDA approval in 10 years for a first-line hepatocellular carcinoma treatment with Lenvima, but challengers are on the horizon. The companies' recent partnership and plans for combination therapy with Keytruda may defend the drug's standing in liver cancer.